What is the initial approach to managing type 1 and type 2 diabetes?

Initial Approach to Diabetes Management

Type 1 Diabetes: Insulin is Non-Negotiable

All patients with type 1 diabetes require immediate insulin therapy at diagnosis—there is no alternative pharmacologic option. 1

Insulin Initiation Strategy

• Start with multiple daily injections (MDI) or insulin pump therapy using both basal and prandial insulin from the outset 1
• For patients with diabetic ketoacidosis (DKA): Begin intravenous insulin until acidosis resolves, then transition to subcutaneous insulin 1
• For stable presentations without ketoacidosis: Initiate subcutaneous basal-bolus insulin regimen immediately 1

Advanced Technology Considerations

• Sensor-augmented insulin pumps with low glucose threshold suspend should be considered for patients experiencing frequent nocturnal hypoglycemia or hypoglycemia unawareness 1
• Continuous glucose monitoring (CGM) is strongly recommended to guide insulin adjustments and prevent hypoglycemia 1

Critical Pitfall to Avoid

Do not attempt to use oral agents like metformin as primary therapy in type 1 diabetes—while metformin may be added later to reduce insulin requirements in overweight patients (reducing insulin needs by 6.6 units/day), it cannot replace insulin 1

---

Type 2 Diabetes: Stratified by Presentation Severity

The initial approach to type 2 diabetes depends entirely on the severity of hyperglycemia and presence of metabolic derangement at diagnosis. 1, 2

Algorithm for Initial Treatment Selection

Scenario 1: Mild-to-Moderate Hyperglycemia (A1C <8.5%, asymptomatic, no ketosis)

Start metformin immediately along with lifestyle modifications—this is the only appropriate first-line pharmacologic agent. 1, 2

• Metformin dosing: Begin 500 mg once or twice daily, titrate up to 2,000 mg daily (1,000 mg BID) as tolerated over several weeks 1, 3
• Lifestyle modifications must be concurrent: At least 150 minutes per week of physical activity and 7% weight loss goal 4, 5
• Reassess in 3 months: If A1C remains above target, add a second agent 3, 2

Scenario 2: Marked Hyperglycemia (A1C ≥8.5% or glucose ≥250 mg/dL) WITHOUT Ketoacidosis

Initiate dual therapy immediately: long-acting insulin PLUS metformin. 1

• Insulin glargine starting dose: 0.5 units/kg/day, titrate every 2-3 days based on fasting glucose 1
• Titration algorithm: 3
  • If fasting glucose >180 mg/dL: increase by 4 units
  • If fasting glucose 144-180 mg/dL: increase by 2-3 units
  • If fasting glucose 126-144 mg/dL: increase by 1-2 units
  • Target fasting glucose: 80-130 mg/dL
• Continue metformin throughout insulin therapy—combination is superior to either alone 1, 3

Scenario 3: Ketosis or Diabetic Ketoacidosis

Treat as type 1 diabetes initially with insulin until metabolic stability is achieved. 1

• Intravenous insulin until acidosis resolves, then subcutaneous insulin 1
• Once acidosis clears: Add metformin while continuing insulin 1
• Check pancreatic autoantibodies to distinguish type 1 from type 2 diabetes 1
  • If positive: Continue as type 1 diabetes, discontinue metformin 1
  • If negative: Continue metformin, consider tapering insulin as glucose improves 1

Scenario 4: Severe Hyperglycemia (glucose ≥600 mg/dL)

Assess immediately for hyperglycemic hyperosmolar nonketotic syndrome (HHNK) and initiate intravenous insulin. 1

---

Second-Line Agents When Metformin Fails

If metformin at maximum tolerated dose does not achieve A1C <7% after 3 months, add a second agent based on comorbidities. 1, 3, 2

Prioritized Add-On Therapy Selection

For patients with established cardiovascular disease, heart failure, or chronic kidney disease: Add SGLT2 inhibitor or GLP-1 receptor agonist—these reduce cardiovascular events by 12-26% and kidney disease progression by 24-39% 2

For patients requiring significant weight loss: GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists achieve >5% weight loss in most patients, often exceeding 10% 2

For youth ≥10 years old with inadequate control on metformin: Add GLP-1 receptor agonist (if no personal/family history of medullary thyroid carcinoma or MEN2) 1

For cost-sensitive patients without cardiovascular/renal disease: Sulfonylureas, DPP-4 inhibitors, or thiazolidinediones are alternatives, though they lack cardiovascular outcome benefits 1, 2

---

Essential Monitoring and Follow-Up

• Schedule weekly visits for the first month when initiating insulin, then monthly until A1C <7% is achieved 3
• Assess vitamin B12 levels periodically in all patients on long-term metformin, especially those with neuropathy or anemia 3, 4
• Home glucose monitoring has limited utility in stable type 2 diabetes on oral agents alone but is essential when using insulin 4

---

Critical Pitfalls in Type 2 Diabetes Management

Do not delay insulin initiation in symptomatic patients with A1C ≥8.5%—aggressive early treatment prevents irreversible microvascular complications 3

Do not discontinue metformin when adding insulin—combination therapy reduces insulin requirements and improves outcomes 1, 3

Do not use fixed insulin doses—titrate based on actual glucose readings every 2-3 days until target is reached 1, 3

Do not overlook cardiovascular risk stratification—patients with established ASCVD, heart failure, or CKD require SGLT2i or GLP-1RA regardless of A1C 2